United States - English - NLM (National Library of Medicine)

seton pharmaceuticals - estrogens, conjugated (unii: iu5qr144qx) (estrogens, conjugated - unii:iu5qr144qx) - estrogens, conjugated 0.625 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - conjugated estrogens 0.3mg;  ; conjugated estrogens 0.3mg (includes 3% overage); conjugated estrogens 0.3mg - tablet - 0.3 mg - active: conjugated estrogens 0.3mg   excipient: calcium sulfate carnauba wax glyceryl mono-oleate lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose opaglos clear 98z19173 opalux green shellac stearic acid sucrose titanium dioxide active: conjugated estrogens 0.3mg (includes 3% overage) excipient: calcium sulfate carnauba wax glyceryl mono-oleate lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose opacode white s-8-28905 opalux green shellac stearic acid sucrose titanium dioxide active: conjugated estrogens 0.3mg excipient: carnauba wax hyprolose hypromellose     lactose monohydrate macrogol 400 magnesium stearate microcrystalline cellulose   opacode white ns-78-18011 opadry green 15b21511 sucrose

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - conjugated estrogens 0.625mg;  ; conjugated estrogens 0.625mg (includes 3% overage); conjugated estrogens 0.625mg - tablet - 0.625 mg - active: conjugated estrogens 0.625mg   excipient: calcium sulfate carnauba wax glyceryl mono-oleate lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose opaglos clear 98z19173 shellac stearic acid sucrose titanium dioxide urethane dimethacrylate luting resin active: conjugated estrogens 0.625mg (includes 3% overage) excipient: calcium sulfate carnauba wax glyceryl mono-oleate lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose opacode opalux maroon as-3910 shellac stearic acid sucrose titanium dioxide active: conjugated estrogens 0.625mg excipient: carnauba wax hyprolose hypromellose     lactose monohydrate macrogol 400 magnesium stearate microcrystalline cellulose   opacode white ns-78-18011 opadry maroon 03b16083 sucrose

United States - English - NLM (National Library of Medicine)

method pharmaceuticals, llc - estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768), methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif) - estrogens, esterified 0.625 mg - esterified estrogens and methyltestosterone full strength and esterified estrogens and methyltestosterone half strength are indicated in the treatment of: moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (there is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) esterified estrogens and methyltestosterone full strength and esterified estrogens and methyltestosterone half strength have not been shown to be effective for any purpose during pregnancy and its use may cause severe harm to the fetus (see boxed warning). estrogens should not be used in women with any of the following conditions: 1.       known or suspected cancer of the breast except in appropriately selected patients being treated for metastatic disease. 2.       known or suspected estrogen-dependent ne

United States - English - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768), methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif) - estrogens, esterified 1.25 mg - esterified estrogens and methyltestosterone full and half-strength tablets are indicated in the: esterified estrogens and methyltestosterone full and half-strength tablets should not be used in women with any of the following conditions: methyltestosterone should not be used in: methyltestosterone is classified as a schedule iii controlled substance under the anabolic steroids act of 1990.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - conjugated estrogens, quantity: 0.3 mg - tablet, film coated - excipient ingredients: sucrose; hyprolose; macrogol 400; carnauba wax; hypromellose; lactose monohydrate; microcrystalline cellulose; magnesium stearate; calcium phosphate; powdered cellulose; titanium dioxide; propylene glycol; purified water; isopropyl alcohol; polysorbate 80; quinoline yellow aluminium lake; indigo carmine aluminium lake - oestrogens with or without progestogens should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. 1. premarin is indicated as replacement therapy for oestrogen deficiency states associated with climacteric manifested by: a) moderate to severe vasomotor symptoms associated with oestrogen deficiency in natural and surgical menopause (sweating, hot flushes). periodic re-evaluation with a view to short term treatment is recommended. b) atrophic vaginitis. when prescribing solely for the treatment of symptoms of vaginal atrophy, topical vaginal products should be considered. there is no evidence that oestrogens are effective for anxiety or depression without associated vasomotor symptoms, and they should not be used to treat such conditions. 2. premarin is indicated for the prevention of postmenopausal osteoporosis in select patients. when prescribed solely for the prevention of postmenopausal osteoporosis, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of premarin should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing. (see precautions and dosage and administration). 3. hypoestrogenic states e.g. female hypogonadism, primary ovarian failure or female castration. see boxed warning, particularly when considering premarin for long-term usage.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - conjugated oestrogens - oral tablet - 625microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - conjugated oestrogens - oral tablet - 625microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - conjugated oestrogens - oral tablet - 1.25mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - conjugated oestrogens - oral tablet - 1.25mg